- Home
- About
- Team
- Today's Market
- Premium
- Research it
- Outlook
- Portfolio
- Mobile
- Trust Equitymaster
- Help
- Free Reports
MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - indian pharma
- ALEMBIC PHARMA - TORRENT PHARMA
ALEMBIC PHARMA vs TORRENT PHARMA - Comparison Results
Current Valuations
| ALEMBIC PHARMA | TORRENT PHARMA | ALEMBIC PHARMA/ TORRENT PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 19.9 | 34.5 | 57.7% | View Chart |
| P/BV | x | 5.2 | 5.2 | 100.5% | View Chart |
| Dividend Yield | % | 0.9 | 1.0 | 86.0% |
Financials
 ALEMBIC PHARMA  TORRENT PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ALEMBIC PHARMA Mar-16 |
TORRENT PHARMA Mar-17 |
ALEMBIC PHARMA/ TORRENT PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 792 | 1,768 | 44.8% | |
| Low | Rs | 443 | 1,186 | 37.4% | |
| Sales per share (Unadj.) | Rs | 167.0 | 346.1 | 48.3% | |
| Earnings per share (Unadj.) | Rs | 38.2 | 55.2 | 69.2% | |
| Cash flow per share (Unadj.) | Rs | 42.0 | 73.3 | 57.3% | |
| Dividends per share (Unadj.) | Rs | 4.00 | 14.00 | 28.6% | |
| Dividend yield (eoy) | % | 0.6 | 0.9 | 68.3% | |
| Book value per share (Unadj.) | Rs | 84.9 | 257.1 | 33.0% | |
| Shares outstanding (eoy) | m | 188.52 | 169.22 | 111.4% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 3.7 | 4.3 | 86.6% | |
| Avg P/E ratio | x | 16.2 | 26.8 | 60.4% | |
| P/CF ratio (eoy) | x | 14.7 | 20.1 | 73.0% | |
| Price / Book Value ratio | x | 7.3 | 5.7 | 126.6% | |
| Dividend payout | % | 10.5 | 25.4 | 41.3% | |
| Avg Mkt Cap | Rs m | 116,383 | 249,887 | 46.6% | |
| No. of employees | `000 | NA | 11.8 | 0.0% | |
| Total wages/salary | Rs m | 4,214 | 9,934 | 42.4% | |
| Avg. sales/employee | Rs Th | NM | 4,971.5 | - | |
| Avg. wages/employee | Rs Th | NM | 843.2 | - | |
| Avg. net profit/employee | Rs Th | NM | 792.4 | - | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 31,487 | 58,569 | 53.8% | |
| Other income | Rs m | 55 | 2,233 | 2.5% | |
| Total revenues | Rs m | 31,542 | 60,802 | 51.9% | |
| Gross profit | Rs m | 10,060 | 13,773 | 73.0% | |
| Depreciation | Rs m | 722 | 3,069 | 23.5% | |
| Interest | Rs m | 37 | 2,056 | 1.8% | |
| Profit before tax | Rs m | 9,356 | 10,881 | 86.0% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | -2 | 0 | - | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 2,160 | 1,545 | 139.8% | |
| Profit after tax | Rs m | 7,194 | 9,336 | 77.1% | |
| Gross profit margin | % | 31.9 | 23.5 | 135.9% | |
| Effective tax rate | % | 23.1 | 14.2 | 162.6% | |
| Net profit margin | % | 22.8 | 15.9 | 143.3% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 15,066 | 53,841 | 28.0% | |
| Current liabilities | Rs m | 7,674 | 31,612 | 24.3% | |
| Net working cap to sales | % | 23.5 | 38.0 | 61.8% | |
| Current ratio | x | 2.0 | 1.7 | 115.3% | |
| Inventory Days | Days | 67 | 97 | 68.9% | |
| Debtors Days | Days | 41 | 84 | 48.5% | |
| Net fixed assets | Rs m | 8,237 | 42,079 | 19.6% | |
| Share capital | Rs m | 377 | 846 | 44.6% | |
| "Free" reserves | Rs m | 15,416 | 42,655 | 36.1% | |
| Net worth | Rs m | 16,005 | 43,501 | 36.8% | |
| Long term debt | Rs m | 0 | 22,408 | 0.0% | |
| Total assets | Rs m | 24,594 | 101,250 | 24.3% | |
| Interest coverage | x | 255.2 | 6.3 | 4,055.7% | |
| Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
| Sales to assets ratio | x | 1.3 | 0.6 | 221.3% | |
| Return on assets | % | 29.4 | 11.3 | 261.3% | |
| Return on equity | % | 44.9 | 21.5 | 209.4% | |
| Return on capital | % | 58.7 | 19.6 | 298.9% | |
| Exports to sales | % | 55.7 | 0 | - | |
| Imports to sales | % | 10.4 | 0 | - | |
| Exports (fob) | Rs m | 17,551 | NA | - | |
| Imports (cif) | Rs m | 3,283 | NA | - | |
| Fx inflow | Rs m | 17,811 | 20,066 | 88.8% | |
| Fx outflow | Rs m | 5,318 | 5,304 | 100.3% | |
| Net fx | Rs m | 12,493 | 14,762 | 84.6% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 9,304 | 10,127 | 91.9% | |
| From Investments | Rs m | -3,105 | -7,869 | 39.5% | |
| From Financial Activity | Rs m | -1,959 | -1,918 | 102.1% | |
| Net Cashflow | Rs m | 4,240 | 212 | 2,004.7% | |
Share Holding
| Indian Promoters | % | 74.1 | 71.5 | 103.6% | |
| Foreign collaborators | % | 0.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 2.9 | 7.0 | 41.3% | |
| FIIs | % | 9.1 | 12.6 | 72.2% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 13.9 | 8.8 | 158.0% | |
| Shareholders | 49,328 | 26,511 | 186.1% | ||
| Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare ALEMBIC PHARMA With: ALKEM LABORATORIES FRESENIUS KABI ONCO. GLENMARK PHARMA ABBOTT INDIA STRIDES SHASUN LTD
Compare ALEMBIC PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Extends Losses; Pharma Stocks Top Losers(Closing)
After opening the day in red share markets in India witnessed negative trading activity throughout the day, and ended well below the dotted line.
Related Views on News
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)
Feb 9, 2018US business was hit by pricing pressure although there was growth sequentially led by new product launches.
Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)
Feb 9, 2018Price erosion in generic US drugs continues but seems to be bottoming out.
Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)
Feb 2, 2018Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
More Views on NewsMost Popular
My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)
May 16, 2018The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.
How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)
May 17, 2018A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.
Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)
May 17, 2018Home loans continue to grow, despite falling sales. What explains this phenomenon?
Looking Beyond the Colourful Prism of This Airline Company(Sector Info)
May 10, 2018Can Interglobe Aviation Safely Fly Out of Turbulence?
HDFC Prudence Fund Now HDFC Balanced Advantage Fund - Time To Sell?(Outside View)
May 9, 2018PersonalFN provides detail analysis on HDFC Balanced Advantage Fund (erstwhile HDFC Prudence Fund and HDFC Growth Fund).
More|
| |
ALEMBIC PHARMA SHARE PRICE
May 21, 2018 (Close)
TRACK ALEMBIC PHARMA
- Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ALEMBIC PHARMA
ALEMBIC PHARMA 5-YR ANALYSIS
COMPARE ALEMBIC PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | Advertise | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.